 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Hemoglobin A1c is a blood test that measures blood sugar control over the previous 3 months. Lower hemoglobin A1c values mean better blood sugar control. Several organizations have developed recommendations for target hemoglobin A1c values for patients with type 2 diabetes.
SUMMARIES FOR PATIENTS
Control of Blood Sugar in Type 2 Diabetes: A Guidance Statement from the American College of Physicians
18 September 2007 | Volume 147 Issue 6 | Page I-52
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Glycemic Control and Type 2 Diabetes Mellitus: The Optimal Hemoglobin A1c Targets. A Guidance Statement from the American College of Physicians." It is in the 18 September 2007 issue of Annals of Internal Medicine (volume 147, pages 417-422). The authors are A. Qaseem, S. Vijan, V. Snow, J.T. Cross, K.B. Weiss, and D.K. Owens, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians.
Who developed these guidelines?
The American College of Physicians (ACP) developed these recommendations. Members of the ACP are internists, specialists in the care of adults.
What is the problem and what is known about it so far?
Type 2 diabetes interferes with the body's ability to store energy from food and results in high blood sugar levels. Over time, high blood sugar levels can lead to many complications, including blindness, kidney failure, nerve damage, and cardiovascular disease (heart disease and stroke). Fortunately, good care with diet, exercise, and medications to control blood sugar levels prevents or delays the development of diabetes-related complications.
How did the ACP develop these recommendations?
The authors searched computerized databases for published English-language guidelines about targets for blood sugar control in patients with type 2 diabetes. After identifying the guidelines, they evaluated them according to 23 criteria related to the quality of health care guidelines.
What did the authors find?
Guidelines that addressed blood sugar control in patients with type 2 diabetes were from the following organizations: American Association of Clinical Endocrinologists, American Academy of Family Physicians, American Diabetes Association, American Geriatrics Society, Canadian Diabetes Association, Institute for Clinical Systems Improvement, National Institute for Health and Clinical Excellence, Scottish Intercollegiate Network, and the Veterans Health Administration. All but one of the guidelines recommended a specific target value for hemoglobin A1c. Among those that did, most recommended a target hemoglobin A1c value of about 7%, but several guidelines recommended customizing the target to the individual patient. For example, lower targets should be used for people at high risk for complications, and higher targets should be used for people who have limited life expectancies because of advanced age or other diseases in addition to diabetes.
What does the ACP suggest that patients and doctors do?
Patients with type 2 diabetes should discuss the benefits and harms of specific levels of sugar control with their doctors. In general, patients should aim for hemoglobin A1c values that are as low as possible without causing unacceptable burden or frequent episodes of dangerously low blood sugar. A hemoglobin A1c value less than 7% is a reasonable target for many patients. Doctors should base the target hemoglobin A1c on each patient's risk of diabetes complications, presence of diseases other than diabetes, life expectancy, and patient preferences. More research is needed about the best targets for blood sugar control, particularly for patients who have other diseases in addition to type 2 diabetes.
What are the cautions related to these recommendations?
Recommendations may change as new studies become available. The authors did not examine guidelines published in languages other than English.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  E. Nagy, J. Watine, P. S. Bunting, R. Onody, W. P. Oosterhuis, D. Rogic, S. Sandberg, K. Boda, and A. R. Horvath Do Guidelines for the Diagnosis and Monitoring of Diabetes Mellitus Fulfill the Criteria of Evidence-Based Guideline Development? Clin. Chem., November 1, 2008; 54(11): 1872 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Aron and L. Pogach Quality indicators for diabetes mellitus in the ambulatory setting: using the Delphi method to inform performance measurement development Qual. Saf. Health Care, October 1, 2008; 17(5): 315 - 317. [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Bainbridge, C. C. Cowie, K. F. Rust, and J. E. Fradkin Mitigating Case Mix Factors by Choice of Glycemic Control Performance Measure Threshold Diabetes Care, September 1, 2008; 31(9): 1754 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Huang, Q. Zhang, N. Gandra, M. H. Chin, and D. O. Meltzer The Effect of Comorbid Illness and Functional Status on the Expected Benefits of Intensive Glucose Control in Older Patients with Type 2 Diabetes: A Decision Analysis Ann Intern Med, July 1, 2008; 149(1): 11 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Palda, I. D. Graham, D. Davis, J. Burgers, M. Brouwers, F. Cluzeau, and On behalf of the AGREE research trust Guideline Adaptation: An Appealing Alternative to De Novo Guideline Development Ann Intern Med, April 1, 2008; 148(7): 564 - 564. [Full Text] [PDF]
|
|
|
|
|
|
B. Fervers, M. Remy-Stockinger, I. D. Graham, B. Burnand, M. Harrison, G. Browman, and J. Latreille Guideline Adaptation: An Appealing Alternative to De Novo Guideline Development Ann Intern Med, April 1, 2008; 148(7): 563 - 564. [Full Text] [PDF]
|
|
|
|
 |
|
 Optimal Hemoglobin A1c Targets: Guidance from the ACP Journal Watch (General), October 9, 2007; 2007(1009): 2 - 2. [Full Text]
|
|
Read all Rapid Responses
| |||||||||||||||||||||||||||||||||||||||||||||||||
Article
